pharmaceuticals-and-healthcare

Global Alzheimers Disease Drug Market Research Report 2017


Published On : Mar 2017

Category : Pharmaceutical

No. of Pages : 120 pages

  • $2900
  • $5800

Please click below to avail discount on this report

This report studies the Alzheimers Disease Drug market status and outlook of global and major regions, from angles of players, regions, product types and end industries; this report analyzes the top players in global and major regions, and splits the Alzheimers Disease Drug market by product type and applications/end industries.

In the last several years, global market of alzheimers disease drug change huge. In 2016, global revenue of alzheimers disease drug is nearly 3161.3 M USD. And the global growth rate is at -10.95% from 2012 to 2016


The major players in global Alzheimers Disease Drug market include
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck.

Geographically, this report is segmented into several key Regions, with Sales, Sales, revenue, Market Share (%) and Growth Rate (%) of Alzheimers Disease Drug in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
China
Japan
Row


On the basis of product, the Alzheimers Disease Drug market is primarily split into
Donepezil
Memantine
Rivastigmine


On the basis on the end users/applications, this report covers
Early to Moderate Stages
Moderate to Severe Stages




In the recent times, the global market for Global alzheimers disease drug market research report 2017 has surfaced as one of the most promising markets in the pharmaceutical industry, thanks to the significant rise in research and development activities by leading vendors of Global alzheimers disease drug market research report 2017 across the world. Manufacturers have turned to technological innovations and data-driven customization to satisfy the augmenting consumer demand for efficiency and more accuracy in results, leading to an increased usage of technology in the Global alzheimers disease drug market research report 2017 production processes, which is also reflecting positively on the growth of this market.

The research report on the Global alzheimers disease drug market research report 2017 is an analytical study which comprehensively analyzes the competitive framework of this market. Using a number of effective assessment tools, such as porter’s five forces and value chain analysis, it performs in-depth analyses of the production and supply as well as the demand and sales of Global alzheimers disease drug market research report 2017 and provides deep insights into the future prospects of this market.

The study begins with a detailed overview of the market for Global alzheimers disease drug market research report 2017, including the definition, classification, and industry chain structure of Global alzheimers disease drug market research report 2017, and move forward to cover every aspect of this market, counting several criteria based on which the market is classified. Focusing specifically on the key trends, it further evaluates the overall performance of this market during the assessment period. With chemical industry undergoing a phase of technological disruption, innovations in products are likely to shape the future of the Global alzheimers disease drug market research report 2017.

In this research report, apart from the trends, the driving forces, restraints, and opportunities have also been taken into consideration to determine the market’s future. Further, it offers an estimation of the market size in terms of value (US$) and in volume (kilo tons) and talks about the key segments and the geographical subdivisions of the market for Global alzheimers disease drug market research report 2017 in details. It provides in-depth information on the development trends and the policies and regulations, concerning Global alzheimers disease drug market research report 2017, implemented in each of the geographical segments. The predominant applications of the Global alzheimers disease drug market research report 2017 have also been discussed at length in this research study.

With all these analyses and information, this report can act as a valuable guide to readers looking to gain a clear understanding of all the factors that are influencing the market for Global alzheimers disease drug market research report 2017 at present and are projected to remain doing so over the forecast period. Readers will also benefit significantly from the important information regarding this market, provided in the forms of figures and tables in the research report.

Additionally, the information on the latest developments in this market, both, at the global as well as regional level, is expected to enhance the decision-making capability of the reader. Up-to-date information on various specifications, buyer analysis, their purchasing volume, prices, and price analysis, and deep insights on the leading suppliers have also been provided in this study for the readers.

At last, the report offers key industry recommendations to companies looking to venture into the Global alzheimers disease drug market research report 2017 from both the perspectives, i.e. demand and supply. The main objective of this research study is to assist stakeholders operating in this market in creating efficient counter strategies to gain an edge over their competitors.

List of Tables and Figures

Figure Product Picture of Alzheimers Disease Drug1
Table Alzheimers Disease Drug Segment by Types2
Figure Global Alzheimers Disease Drug Sales Market Share (%) by Types in 20163
Figure Product Picture of Donepezil4
Figure Product Picture of Memantine4
Figure Product Picture of Rivastigmine5
Table Global Alzheimers Disease Drug Segment by Applications5
Table Treatments at a Glance6
Figure North America Alzheimers Disease Drug Revenue (M USD) and Growth Rate (%) (2012-2022)7
Figure China Alzheimers Disease Drug Revenue (M USD) and Growth Rate (%) (2012-2022)8
Figure Europe Alzheimers Disease Drug Revenue (M USD) and Growth Rate (%) (2012-2022)9
Figure Japan Alzheimers Disease Drug Revenue (M USD) and Growth Rate (%) (2012-2022)10
Figure Global Alzheimers Disease Drug Revenue (M USD) Status and Outlook (2012-2022)11
Figure Global Alzheimers Disease Drug Sales (M Units) Status and Outlook (2012-2022)12
Figure Global Alzheimers Disease Drug Sales Market Share (%) by Applications in 201613
Table Global Alzheimers Disease Drug Sales (M Units) of Key Manufacturers (2012-2017)14
Figure 2016 Alzheimers Disease Drug Sales Share (%) by Manufacturers15
Figure 2017 Alzheimers Disease Drug Sales Share (%) by Manufacturers16
Table Global Alzheimers Disease Drug Revenue (M USD) by Manufacturers (2012-2017)16
Table 2016 Global Alzheimers Disease Drug Revenue Share (%) by Manufacturers17
Table 2017 Global Alzheimers Disease Drug Revenue Share (%) by Manufacturers18
Table Global Market Alzheimers Disease Drug Average Price (USD/Unit) of Key Manufacturers (2012-2017)18
Figure Global Market Alzheimers Disease Drug Average Price (USD/Unit) of Key Manufacturers in 201619
Table Manufacturers Alzheimers Disease Drug Headquarters and Found Date19
Table Manufacturers Alzheimers Disease Drug Brand20
Table 2016 Global Alzheimers Disease Drug Revenue Share (%) by Manufacturers21
Figure Alzheimers Disease Drug Market Share (%) of Top 3 Manufacturers22
Figure Alzheimers Disease Drug Market Share (%) of Top 5 Manufacturers23
Table Mergers & Acquisitions, Expansion23
Table Global Alzheimers Disease Drug Sales (M Units) by Regions (2012-2017)27
Table Global Alzheimers Disease Drug Sales Market Share by Regions (2012-2017)27
Figure 2016 Global Alzheimers Disease Drug Sales Market Share (%) by Regions28
Figure 2017 Global Alzheimers Disease Drug Sales Market Share (%) by Regions28
Table Global Alzheimers Disease Drug Revenue (M USD) by Regions (2012-2017)29
Table Global Alzheimers Disease Drug Revenue Market Share (%) by Regions (2012-2017)29
Figure 2016 Global Alzheimers Disease Drug Revenue Market Share (%) by Regions30
Figure 2017 Global Alzheimers Disease Drug Revenue Market Share (%) by Regions30
Table Global Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)31
Table North America Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)31
Table Europe Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)32
Table China Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)32
Table Japan Alzheimers Disease Drug Sales (M Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)33
Table Global Alzheimers Disease Drug Sales (M Units) by Types (2012-2017)34
Table Global Alzheimers Disease Drug Sales Share (%) by Types (2012-2017)34
Figure 2016 Sales Market Share (%) of Alzheimers Disease Drug by Types35
Figure 2017 Sales Market Share (%) of Alzheimers Disease Drug by Types35
Table Global Alzheimers Disease Drug Revenue (M USD) by Types (2012-2017)36
Table Global Alzheimers Disease Drug Revenue Share (%) by Types (2012-2017)36
Figure 2016 Revenue Market Share (%) of Alzheimers Disease Drug by Types36
Figure 2017 Revenue Market Share (%) of Alzheimers Disease Drug by Types37
Table Global Alzheimers Disease Drug Price (USD/Unit) by Types (2012-2017)37
Figure Global Alzheimers Disease Drug Sales Growth (%) by Type (2012-2017)38
Table Global Alzheimers Disease Drug Sales (M Units) by Applications (2012-2017)39
Table Global Alzheimers Disease Drug Sales Market Share (%) by Applications (2012-2017)39
Figure Global Alzheimers Disease Drug Sales Market Share (%) by Applications in 201640
Figure Global Alzheimers Disease Drug Sales Market Share (%) by Applications in 201740
Figure Global Alzheimers Disease Drug Sales Growth Rate (%) by Applications (2012-2017)41
Table Allergan Company Profile42
Table Alzheimers Disease Drug Product Introduction of Allergan43
Table Alzheimers Disease Drug Ssles (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Allergan 2012-201744
Table Eisai Company Profile44
Table Alzheimers Disease Drug Product Introduction of Eisai45
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Eisai 2012-201746
Table Novartis Company Profile46
Table Alzheimers Disease Drug Product Introduction of Novartis47
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Novartis 2012-201748
Table Daiichi Sankyo Company Profile48
Table Alzheimers Disease Drug Product Introduction of Daiichi Sankyo49
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Daiichi Sankyo 2012-201750
Table Merz Pharma Company Profile50
Table Alzheimers Disease Drug Product Introduction of Merz Pharma51
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Merz Pharma 2012-201752
Table Pfizer Company Profile52
Table Alzheimers Disease Drug Product Introduction of Pfizer53
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Pfizer 2012-201754
Table Johnson & Johnson Company Profile54
Table Alzheimers Disease Drug Product Introduction of Johnson & Johnson55
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Johnson & Johnson 2012-201756
Table Lundbeck Company Profile56
Table Alzheimers Disease Drug Product Introduction of Lundbeck57
Table Alzheimers Disease Drug Production (M Unit), Price (USD/Unit), Cost (USD/Unit), Gross (USD/Unit), Revenue (M USD) and Gross Margin of Lundbeck 2012-201758
Figure typical phases from research to the market for a drug candidate60
Table Out-of-pocket Preclinical and Clinical Period Cost per Investigational Biopharmaceutical Compound61
Table Capitalized Preclinical and Clinical Period costs per Investigational Biopharmaceutical Compound61
Figure Manufacturing Cost Structure of Alzheimers Disease Drug62
Figure Assessment of API Manufacturing Cost By Region63
Figure 2016 Manufacturing Labor Cost Per Hour in China as a Proportion of Those in Other Countries (%)64
Figure Manufacturing Labor Costs in Select Provinces and Countries in 201664
Figure 2016 Global Manufacturing Competitiveness Index rankings by country65
Figure US Nonfarm Unit Labor Cost 2014-201666
Figure United States Average Hourly Wages (USD/H) 2016-201766
Figure China Labor Cost Index 2014-201667
Figure China Average Yearly Wages 2006-201667
Figure Euro Area Labor Cost 2014-201668
Figure Japan Overview of Average Monthly Wages 2012-2017(JPY Thousand/Month)68
Figure Manufacturing Process Analysis of Alzheimers Disease Drug69
Figure Alzheimers Disease Drug Industrial Chain Analysis70
Table Major Buyers of Alzheimers Disease Drug71
Figure Marketing Channel for Alzheimers Disease73
Figure Alzheimers Disease Marketing Channel74
Table Distributors/Traders List78
Figure Agents currently in clinical trials for AD80
Table Agents currently in phase III of development and their mechanism of action80
Table Agents currently in phase II of AD drug development and their mechanism of action83
Table Agents currently in phase I of development and their mechanism of action88
Table Percent of trials with specific biomarkers included91
Figure Global Alzheimers Disease Drug Sales (M Units) and Growth Rate (%) Forecast (2017-2022)92
Figure Global Alzheimers Disease Drug Revenue (M USD) and Growth Rate (%) Forecast (2017-2022)93
Figure Global Alzheimers Disease Drug Price and Trend Forecast (2017-2022)94
Table Global Alzheimers Disease Drug Sales (M Units) Forecast by Regions (2017-2022)94
Figure North America Alzheimers Disease Drug Sales (M Units) and Growth Rate (%) Forecast (2017-2022)95
Figure North America Alzheimers Disease Drug Revenue and Growth Rate (%) Forecast (2017-2022)96
Figure Europe Alzheimers Disease Drug Sales (M Units) and Growth Rate (%) Forecast (2017-2022)97
Figure Europe Alzheimers Disease Drug Revenue and Growth Rate (%) Forecast (2017-2022)98
Figure China Alzheimers Disease Drug Sales (M Units) and Growth Rate (%) Forecast (2017-2022)99
Figure China Alzheimers Disease Drug Revenue and Growth Rate (%) Forecast (2017-2022)100
Figure Japan Alzheimers Disease Drug Sales (M Units) and Growth Rate (%) Forecast (2017-2022)101
Figure Japan Alzheimers Disease Drug Revenue and Growth Rate (%) Forecast (2017-2022)102
Table Global Alzheimers Disease Drug Sales (M Unit) Forecast by Type (2017-2022)102
Table Global Alzheimers Disease Drug Revenue (M USD) Forecast by Type (2017-2022)103
Table Global Alzheimers Disease Drug Price (USD/Unit) Forecast by Type (2017-2022)103
Table Global Alzheimers Disease Drug Sales (M Units) Forecast by Application (2017-2022)103
Table Research Programs/Design for This Report105
Figure Bottom-up and Top-down Approaches for This Report107
Figure Data Triangulation108
Table Key Data Information from Secondary Sources109
Table Key Data Information from Primary Sources109

Send an Enquiry

  • * :
  • * :
  • * :
  • * :
  • * :
  • :
  • * :
  • * indicates required field.

LATEST NEWS


Back To Top